AstraZeneca PLC
AZNCF
$135.88
$0.520.38%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 54.98B | 54.07B | 51.21B | 49.13B | 47.61B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.98B | 54.07B | 51.21B | 49.13B | 47.61B |
| Cost of Revenue | 9.67B | 9.66B | 8.93B | 8.56B | 8.35B |
| Gross Profit | 45.31B | 44.42B | 42.28B | 40.57B | 39.26B |
| SG&A Expenses | 19.49B | 19.55B | 18.18B | 18.37B | 18.46B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -239.00M | -192.00M | -222.00M | -267.00M | -991.00M |
| Total Operating Expenses | 41.59B | 41.36B | 38.54B | 37.82B | 36.75B |
| Operating Income | 13.39B | 12.71B | 12.67B | 11.31B | 10.87B |
| Income Before Tax | 9.29B | 8.69B | 7.92B | 7.75B | 7.44B |
| Income Tax Expenses | 1.51B | 1.65B | 1.42B | 1.30B | 1.10B |
| Earnings from Continuing Operations | 7.78K | 7.04K | 6.50K | 6.45K | 6.34K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -10.00M | -6.00M | -5.00M | -5.00M | -6.00M |
| Net Income | 7.77B | 7.04B | 6.50B | 6.44B | 6.33B |
| EBIT | 13.39B | 12.71B | 12.67B | 11.31B | 10.87B |
| EBITDA | 18.06B | 17.35B | 17.39B | 15.94B | 15.47B |
| EPS Basic | 5.01 | 4.54 | 4.19 | 4.16 | 4.09 |
| Normalized Basic EPS | 4.90 | 4.61 | 4.61 | 4.05 | 3.86 |
| EPS Diluted | 4.98 | 4.51 | 4.16 | 4.13 | 4.06 |
| Normalized Diluted EPS | 4.87 | 4.58 | 4.57 | 4.02 | 3.83 |
| Average Basic Shares Outstanding | 6.20B | 6.20B | 6.20B | 6.20B | 6.20B |
| Average Diluted Shares Outstanding | 6.25B | 6.24B | 6.24B | 6.24B | 6.24B |
| Dividend Per Share | 3.10 | 3.10 | 2.97 | 2.97 | 2.90 |
| Payout Ratio | 63.60% | 65.80% | 71.25% | 69.29% | 70.56% |